Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/101235Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 張晏禎 | zh_TW |
| dc.contributor.advisor | Yen-Chen Chang | en |
| dc.contributor.author | 鄭乃維 | zh_TW |
| dc.contributor.author | Nai-Wei Cheng | en |
| dc.date.accessioned | 2025-12-31T16:25:06Z | - |
| dc.date.available | 2026-01-01 | - |
| dc.date.copyright | 2025-12-31 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-12-05 | - |
| dc.identifier.citation | [1] Alonso, L., & Fuchs, E. (2003). Stem cells in the skin: waste not, Wnt not. Genes Dev, 17(10), 1189-1200. https://doi.org/10.1101/gad.1086903
[2] Amit, S., Hatzubai, A., Birman, Y., Andersen, J. S., Ben-Shushan, E., Mann, M., Ben-Neriah, Y., & Alkalay, I. (2002). Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev, 16(9), 1066-1076. https://doi.org/10.1101/gad.230302 [3] Baarsma, H. A., Königshoff, M., & Gosens, R. (2013). The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacol Ther, 138(1), 66-83. https://doi.org/10.1016/j.pharmthera.2013.01.002 [4] Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005). Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res, 65(20), 9226-9235. https://doi.org/10.1158/0008-5472.Can-05-1699 [5] Bänziger, C., Soldini, D., Schütt, C., Zipperlen, P., Hausmann, G., & Basler, K. (2006). Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell, 125(3), 509-522. https://doi.org/10.1016/j.cell.2006.02.049 [6] Barham, W., Frump, A. L., Sherrill, T. P., Garcia, C. B., Saito-Diaz, K., VanSaun, M. N., Fingleton, B., Gleaves, L., Orton, D., Capecchi, M. R., Blackwell, T. S., Lee, E., Yull, F., & Eid, J. E. (2013). Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov, 3(11), 1286-1301. https://doi.org/10.1158/2159-8290.Cd-13-0138 [7] Bartscherer, K., Pelte, N., Ingelfinger, D., & Boutros, M. (2006). Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell, 125(3), 523-533. https://doi.org/10.1016/j.cell.2006.04.009 [8] Bentzen, S. M. (2006). Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer, 6(9), 702-713. https://doi.org/10.1038/nrc1950 [9] Bostock, D. E., & Dye, M. T. (1979). Prognosis after surgical excision of fibrosarcomas in cats. J Am Vet Med Assoc, 175(7), 727-728. [10] Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., Bioulac-Sage, P., Laurent-Puig, P., & Zucman-Rossi, J. (2007). Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 45(1), 42-52. https://doi.org/10.1002/hep.21467 [11] Briski, L. M., Thomas, D. G., Patel, R. M., Lawlor, E. R., Chugh, R., McHugh, J. B., & Lucas, D. R. (2018). Canonical Wnt/β-catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma. Rare Tumors, 10, 2036361318813431. https://doi.org/10.1177/2036361318813431 [12] Canesin, G., Evans-Axelsson, S., Hellsten, R., Krzyzanowska, A., Prasad, C. P., Bjartell, A., & Andersson, T. (2017). Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One, 12(9), e0184418. https://doi.org/10.1371/journal.pone.0184418 [13] Cantilena, S., Pastorino, F., Pezzolo, A., Chayka, O., Pistoia, V., Ponzoni, M., & Sala, A. (2011). Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget, 2(12), 976-983. https://doi.org/10.18632/oncotarget.410 [14] Cecco, B. S., Henker, L. C., De Lorenzo, C., Schwertz, C. I., Bianchi, R. M., da Costa, F. V. A., Driemeier, D., Pavarini, S. P., & Sonne, L. (2019). Epidemiological and Pathological Characterization of Feline Injection Site Sarcomas in Southern Brazil. J Comp Pathol, 172, 31-36. https://doi.org/10.1016/j.jcpa.2019.08.009 [15] Cha, J. Y., Jung, J.-E., Emami, K., Briaud, I., Tenzin, F., Pyon, Y., Lee, D., Chung, J. U., Lee, J. H., Oh, S.-W., Jung, K. Y., & Pai, J. K. (2010). Abstract LB-176: Discovery of CWP232291: A novel and potent small molecule inhibitor of Wnt signaling in hematological malignacies. Cancer Research, 70(8_Supplement), LB-176-LB-176. https://doi.org/10.1158/1538-7445.AM10-LB-176 [16] Cheah, P. Y., Choo, P. H., Yao, J., Eu, K. W., & Seow-Choen, F. (2002). A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer, 95(12), 2479-2486. https://doi.org/10.1002/cncr.10986 [17] Chen, C., Zhao, M., Tian, A., Zhang, X., Yao, Z., & Ma, X. (2015). Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget, 6(19), 17570-17583. https://doi.org/10.18632/oncotarget.4100 [18] Choi, H. J., Huber, A. H., & Weis, W. I. (2006). Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem, 281(2), 1027-1038. https://doi.org/10.1074/jbc.M511338200 [19] Chung, H., Creger, E., Sitts, L., Chiu, K., Mak, C.-C., Kc, S., Tam, B., Bucci, G., Stewart, J., Phalen, T., & Cha, S. (2019a). SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models. Blood, 134, 4059. https://doi.org/https://doi.org/10.1182/blood-2019-124812 [20] Chung, H., Creger, E., Sitts, L., Chiu, K., Mak, C.-C., Kc, S., Tam, B., Bucci, G., Stewart, J., Phalen, T., & Cha, S. (2019b). SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models. Blood, 134, 3913. https://doi.org/https://doi.org/10.1182/blood-2019-131209 [21] Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell, 127(3), 469-480. https://doi.org/10.1016/j.cell.2006.10.018 [22] Cohen, M., Wright, J. C., Brawner, W. R., Smith, A. N., Henderson, R., & Behrend, E. N. (2001). Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). J Am Vet Med Assoc, 219(11), 1582-1589. https://doi.org/10.2460/javma.2001.219.1582 [23] Corda, G., Sala, G., Lattanzio, R., Iezzi, M., Sallese, M., Fragassi, G., Lamolinara, A., Mirza, H., Barcaroli, D., Ermler, S., Silva, E., Yasaei, H., Newbold, R. F., Vagnarelli, P., Mottolese, M., Natali, P. G., Perracchio, L., Quist, J., Grigoriadis, A.,…Sala, A. (2017). Functional and prognostic significance of the genomic amplification of frizzled 6 () in breast cancer. The Journal of Pathology, 241(3), 350-361. https://doi.org/https://doi.org/10.1002/path.4841 [24] Couto, S. S., Griffey, S. M., Duarte, P. C., & Madewell, B. R. (2002). Feline vaccine-associated fibrosarcoma: morphologic distinctions. Vet Pathol, 39(1), 33-41. https://doi.org/10.1354/vp.39-1-33 [25] Cronin, K., Page, R. L., Spodnick, G., Dodge, R., Hardie, E. N., Price, G. S., Ruslander, D., & Thrall, D. E. (1998). Radiation therapy and surgery for fibrosarcoma in 33 cats. Vet Radiol Ultrasound, 39(1), 51-56. https://doi.org/10.1111/j.1740-8261.1998.tb00325.x [26] Day, M. J., Schoon, H. A., Magnol, J. P., Saik, J., Devauchelle, P., Truyen, U., Gruffydd-Jones, T. J., Cozette, V., Jas, D., Poulet, H., Pollmeier, M., & Thibault, J. C. (2007). A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine, 25(20), 4073-4084. https://doi.org/10.1016/j.vaccine.2007.02.049 [27] Dean, R. S., Pfeiffer, D. U., & Adams, V. J. (2013). The incidence of feline injection site sarcomas in the United Kingdom. BMC Vet Res, 9, 17. https://doi.org/10.1186/1746-6148-9-17 [28] Demunter, A., Libbrecht, L., Degreef, H., De Wolf-Peeters, C., & van den Oord, J. J. (2002). Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol, 15(4), 454-461. https://doi.org/10.1038/modpathol.3880546 [29] Dickson, E. T., & Hyman, P. (2013). Mutation, Silent. In S. Maloy & K. Hughes (Eds.), Brenner's Encyclopedia of Genetics (Second Edition) (pp. 553-555). Academic Press. https://doi.org/https://doi.org/10.1016/B978-0-12-374984-0.01008-1 [30] Dobromylskyj, M. (2022). Feline Soft Tissue Sarcomas: A Review of the Classification and Histological Grading, with Comparison to Human and Canine. Animals (Basel), 12(20). https://doi.org/10.3390/ani12202736 [31] Dohi, O., Ohtani, H., Hatori, M., Sato, E., Hosaka, M., Nagura, H., Itoi, E., & Kokubun, S. (2009). Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology, 55(4), 432-440. https://doi.org/10.1111/j.1365-2559.2009.03399.x [32] Dotan, E., Cardin, D. B., Lenz, H. J., Messersmith, W., O'Neil, B., Cohen, S. J., Denlinger, C. S., Shahda, S., Astsaturov, I., Kapoun, A. M., Brachmann, R. K., Uttamsingh, S., Stagg, R. J., & Weekes, C. (2020). Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res, 26(20), 5348-5357. https://doi.org/10.1158/1078-0432.Ccr-20-0489 [33] Duchartre, Y., Kim, Y. M., & Kahn, M. (2016). The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol, 99, 141-149. https://doi.org/10.1016/j.critrevonc.2015.12.005 [34] Duncan, P. I., Stojdl, D. F., Marius, R. M., Scheit, K. H., & Bell, J. C. (1998). The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing. Exp Cell Res, 241(2), 300-308. https://doi.org/10.1006/excr.1998.4083 [35] El-Khoueiry, A. B., Ning, Y., Yang, D., Cole, S., Kahn, M., Zoghbi, M., Berg, J., Fujimori, M., Inada, T., Kouji, H., & Lenz, H.-J. (2013). A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 31(15_suppl), 2501-2501. https://doi.org/10.1200/jco.2013.31.15_suppl.2501 [36] Ellison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D., & Clifford, S. C. (2005). beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol, 23(31), 7951-7957. https://doi.org/10.1200/jco.2005.01.5479 [37] Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J. L., Kim, H. Y., Moon, S. H., Ha, J. R., & Kahn, M. (2004). A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A, 101(34), 12682-12687. https://doi.org/10.1073/pnas.0404875101 [38] Farin, H. F., Jordens, I., Mosa, M. H., Basak, O., Korving, J., Tauriello, D. V., de Punder, K., Angers, S., Peters, P. J., Maurice, M. M., & Clevers, H. (2016). Visualization of a short-range Wnt gradient in the intestinal stem-cell niche. Nature, 530(7590), 340-343. https://doi.org/10.1038/nature16937 [39] Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., Cain, J., Tam, R., Cheng, C. Y., Evans, J. W., O'Young, G., Song, X., Lewicki, J., Kapoun, A. M., Gurney, A., Yen, W. C., & Hoey, T. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv, 3(6), e1700090. https://doi.org/10.1126/sciadv.1700090 [40] Francis, P., Namløs, H. M., Müller, C., Edén, P., Fernebro, J., Berner, J. M., Bjerkehagen, B., Akerman, M., Bendahl, P. O., Isinger, A., Rydholm, A., Myklebost, O., & Nilbert, M. (2007). Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics, 8, 73. https://doi.org/10.1186/1471-2164-8-73 [41] Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006). Clonogenic assay of cells in vitro. Nature Protocols, 1(5), 2315-2319. https://doi.org/10.1038/nprot.2006.339 [42] Fukukawa, C., Hanaoka, H., Nagayama, S., Tsunoda, T., Toguchida, J., Endo, K., Nakamura, Y., & Katagiri, T. (2008). Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci, 99(2), 432-440. https://doi.org/10.1111/j.1349-7006.2007.00701.x [43] Gama, A., Paredes, J., Gärtner, F., Alves, A., & Schmitt, F. (2008). Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Vet J, 177(1), 45-53. https://doi.org/10.1016/j.tvjl.2007.05.024 [44] Gao, Z. H., Lu, C., Wang, M. X., Han, Y., & Guo, L. J. (2014). Differential β-catenin expression levels are associated with morphological features and prognosis of colorectal cancer. Oncol Lett, 8(5), 2069-2076. https://doi.org/10.3892/ol.2014.2433 [45] Gobar, G. M., & Kass, P. H. (2002). World Wide Web-based survey of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc, 220(10), 1477-1482. https://doi.org/10.2460/javma.2002.220.1477 [46] Gross, J. C., Chaudhary, V., Bartscherer, K., & Boutros, M. (2012). Active Wnt proteins are secreted on exosomes. Nat Cell Biol, 14(10), 1036-1045. https://doi.org/10.1038/ncb2574 [47] Guezguez, B., Almakadi, M., Benoit, Y. D., Shapovalova, Z., Rahmig, S., Fiebig-Comyn, A., Casado, F. L., Tanasijevic, B., Bresolin, S., Masetti, R., Doble, B. W., & Bhatia, M. (2016). GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. Cancer Cell, 29(1), 61-74. https://doi.org/10.1016/j.ccell.2015.11.012 [48] Hahn, K. A., Endicott, M. M., King, G. K., & Harris-King, F. D. (2007). Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989–1999). Journal of the American Veterinary Medical Association, 231(5), 742-745. https://doi.org/10.2460/javma.231.5.742 [49] Han, J. I., Kim, D. Y., & Na, K. J. (2010). Dysregulation of the Wnt/beta-catenin signaling pathway in canine cutaneous melanotic tumor. Vet Pathol, 47(2), 285-291. https://doi.org/10.1177/0300985809359303 [50] Han, J. I., Kim, Y., Kim, D. Y., & Na, K. J. (2012). Alteration in E-Cadherin/β-Catenin Expression in Canine Melanotic Tumors. Veterinary Pathology, 50(2), 274-280. https://doi.org/10.1177/0300985812457792 [51] Hanaoka, H., Katagiri, T., Fukukawa, C., Yoshioka, H., Yamamoto, S., Iida, Y., Higuchi, T., Oriuchi, N., Paudyal, B., Paudyal, P., Nakamura, Y., & Endo, K. (2009). Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med, 23(5), 479-485. https://doi.org/10.1007/s12149-009-0265-1 [52] Hart, M., Concordet, J. P., Lassot, I., Albert, I., del los Santos, R., Durand, H., Perret, C., Rubinfeld, B., Margottin, F., Benarous, R., & Polakis, P. (1999). The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol, 9(4), 207-210. https://doi.org/10.1016/s0960-9822(99)80091-8 [53] Hartmann, K., Day, M. J., Thiry, E., Lloret, A., Frymus, T., Addie, D., Boucraut-Baralon, C., Egberink, H., Gruffydd-Jones, T., Horzinek, M. C., Hosie, M. J., Lutz, H., Marsilio, F., Pennisi, M. G., Radford, A. D., Truyen, U., & Möstl, K. (2015). Feline injection-site sarcoma: ABCD guidelines on prevention and management. J Feline Med Surg, 17(7), 606-613. https://doi.org/10.1177/1098612x15588451 [54] Hawkins, A. G., Basrur, V., da Veiga Leprevost, F., Pedersen, E., Sperring, C., Nesvizhskii, A. I., & Lawlor, E. R. (2018). The Ewing Sarcoma Secretome and Its Response to Activation of Wnt/beta-catenin Signaling. Mol Cell Proteomics, 17(5), 901-912. https://doi.org/10.1074/mcp.RA118.000596 [55] Hendrick, M. J., & Brooks, J. J. (1994). Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol, 31(1), 126-129. https://doi.org/10.1177/030098589403100121 [56] Hendrick, M. J., & Goldschmidt, M. H. (1991). Do injection site reactions induce fibrosarcomas in cats? J Am Vet Med Assoc, 199(8), 968. [57] Herr, P., & Basler, K. (2012). Porcupine-mediated lipidation is required for Wnt recognition by Wls. Dev Biol, 361(2), 392-402. https://doi.org/10.1016/j.ydbio.2011.11.003 [58] Hershey, A. E., Sorenmo, K. U., Hendrick, M. J., Shofer, F. S., & Vail, D. M. (2000). Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc, 216(1), 58-61. https://doi.org/10.2460/javma.2000.216.58 [59] Hirschberger, J. (2003). Principles of treatment for feline lymphoma. Textbook of veterinary internal medicine. 2nd ed. Philadelphia: WB Saunders, 98-102. [60] Hong, L., Li, W., Li, Y., & Yin, S. (2023). Nanoparticle-based drug delivery systems targeting cancer cell surfaces [10.1039/D3RA02969G]. RSC Advances, 13(31), 21365-21382. https://doi.org/10.1039/D3RA02969G [61] Hsueh, C.-S., Wu, C.-H., Shih, C.-H., Yeh, J. L.-S., Jeng, C.-R., Pang, V. F., Chiou, H.-Y., & Chang, H.-W. (2019). Role of nuclear factor-kappa B in feline injection site sarcoma. BMC Veterinary Research, 15(1), 365. https://doi.org/10.1186/s12917-019-2100-9 [62] Hutchinson, M. N. D., Mierzwa, M., & D'Silva, N. J. (2020). Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer. Oncogene, 39(18), 3638-3649. https://doi.org/10.1038/s41388-020-1250-3 [63] Hwang, Deng, X., Byun, S., Lee, C., Lee, S. J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., Mandinova, A., & Lee, S. W. (2016). Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Rep, 16(1), 28-36. https://doi.org/10.1016/j.celrep.2016.05.071 [64] Hwang, S.-Y., Deng, X., Byun, S., Lee, C., Lee, S.-J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., Mandinova, A., & Lee, S. W. (2016). Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Reports, 16(1), 28-36. https://doi.org/https://doi.org/10.1016/j.celrep.2016.05.071 [65] Hwang, S. Y., Deng, X., Byun, S., Lee, C., Lee, S. J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., Mandinova, A., & Lee, S. W. (2016). Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Rep, 16(1), 28-36. https://doi.org/10.1016/j.celrep.2016.05.071 [66] Hwang, W. Y., Kostiuk, V., González, D. P., Lusk, C. P., & Khokha, M. K. (2022). Kap-β2/Transportin mediates β-catenin nuclear transport in Wnt signaling. eLife, 11, e70495. https://doi.org/10.7554/eLife.70495 [67] Ihrke, P. J., Walder, E. J., Affolter, V. K., & Gross, T. L. (2005). Skin diseases of the dog and cat: clinical and histopathologic diagnosis. [68] Ishikawa, K., Chambers, J. K., & Uchida, K. (2024). Activation of the Wnt/β-catenin signaling pathway and CTNNB1 mutations in canine intestinal epithelial proliferative lesions. J Vet Med Sci, 86(7), 748-755. https://doi.org/10.1292/jvms.24-0125 [69] Janku, F., Connolly, R., LoRusso, P., de Jonge, M., Vaishampayan, U., Rodon, J., Argilés, G., Myers, A., Hsu Schmitz, S.-F., Ji, Y., McLaughlin, M., Palmer, M. R., & Morawiak, J. (2015). Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors. Molecular Cancer Therapeutics, 14(12_Supplement_2), C45-C45. https://doi.org/10.1158/1535-7163.TARG-15-C45 [70] Jas, D., Soyer, C., De Fornel-Thibaud, P., Oberli, F., Vernes, D., Guigal, P. M., Poulet, H., & Devauchelle, P. (2015). Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials in Vaccinology, 4, 1-8. https://doi.org/https://doi.org/10.1016/j.trivac.2014.11.001 [71] Jiang, J., Lan, C., Li, L., Yang, D., Xia, X., Liao, Q., Fu, W., Chen, X., An, S., Wang, W. E., & Zeng, C. (2018). A novel porcupine inhibitor blocks WNT pathways and attenuates cardiac hypertrophy. Biochim Biophys Acta Mol Basis Dis, 1864(10), 3459-3467. https://doi.org/10.1016/j.bbadis.2018.07.035 [72] Jimeno, A., Gordon, M., Chugh, R., Messersmith, W., Mendelson, D., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Uttamsingh, S., Brachmann, R. K., & Smith, D. C. (2017). A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res, 23(24), 7490-7497. https://doi.org/10.1158/1078-0432.Ccr-17-2157 [73] Jursza, E., Skarzynski, D. J., & Siemieniuch, M. J. (2014). Validation of reference genes in the feline endometrium. Reproductive Biology, 14(4), 302-306. https://doi.org/https://doi.org/10.1016/j.repbio.2014.04.003 [74] Kass, P. H., Barnes, W. G., Spangler, W. L., Chomel, B. B., & Culbertson, M. R. (1993). Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. Journal of the American Veterinary Medical Association, 203(3), 396-405. https://doi.org/10.2460/javma.1993.203.03.396 [75] Kawasaki, H., Eckner, R., Yao, T. P., Taira, K., Chiu, R., Livingston, D. M., & Yokoyama, K. K. (1998). Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature, 393(6682), 284-289. https://doi.org/10.1038/30538 [76] Khademian, N., Mirzaei, A., Hosseini, A., Zare, L., Nazem, S., Babaheidarian, P., Sheikhi, A., Abdolvahabi, Z., Ibrahimi, M., Jamshidi, K., Rahbar, M., Salimi, V., & Tavakoli-Yaraki, M. (2022). Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors. Sci Rep, 12(1), 9488. https://doi.org/10.1038/s41598-022-13685-1 [77] Khan, N. P., Pandith, A. A., Hussain, M. U., Yousuf, A., Khan, M. S., Wani, K. A., & Mudassar, S. (2011). Novelty of Axin 2 and lack of Axin 1 gene mutation in colorectal cancer: a study in Kashmiri population. Mol Cell Biochem, 355(1-2), 149-155. https://doi.org/10.1007/s11010-011-0848-8 [78] Kim, A., Park, E. Y., Kim, K., Lee, J. H., Shin, D. H., Kim, J. Y., Park, D. Y., Lee, C. H., Sol, M. Y., Choi, K. U., Kim, J. I., & Lee, I. S. (2014). Prognostic significance of WT1 expression in soft tissue sarcoma. World J Surg Oncol, 12, 214. https://doi.org/10.1186/1477-7819-12-214 [79] Kim, S., & Jeong, S. (2019). Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases. Mol Cells, 42(1), 8-16. https://doi.org/10.14348/molcells.2018.0436 [80] Kim, S.-D., Byun, Y.-H., Hur, E.-H., Oh, S.-W., Lee, J. H., Goo, B.-K., Lee, S.-S., Jung, K.-Y., Lee, K.-H., Lee, J.-H., Kim, D.-Y., Choi, Y., & Lee, J.-H. (2011). Abstract 4518: Effects of a novel small molecule inhibitor of Wnt signal pathway, CWP232291, on primary tumor cells from patients with malignant hematologic diseases. Cancer Research, 71(8_Supplement), 4518-4518. https://doi.org/10.1158/1538-7445.AM2011-4518 [81] Kimelman, D., & Xu, W. (2006). beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene, 25(57), 7482-7491. https://doi.org/10.1038/sj.onc.1210055 [82] Kinzler, K. W., Nilbert, M. C., Vogelstein, B., Bryan, T. M., Levy, D. B., Smith, K. J., Preisinger, A. C., Hamilton, S. R., Hedge, P., Markham, A., & et al. (1991). Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science, 251(4999), 1366-1370. https://doi.org/10.1126/science.1848370 [83] Kiupel, M. (2020). Surgical Pathology of Tumors of Domestic Animals: Tumors of soft tissue. Davis-Thompson DVM Foundation. https://books.google.com.tw/books?id=DDq1zQEACAAJ [84] Kleiter, M., Tichy, A., Willmann, M., Pagitz, M., & Wolfesberger, B. (2010). CONCOMITANT LIPOSOMAL DOXORUBICIN AND DAILY PALLIATIVE RADIOTHERAPY IN ADVANCED FELINE SOFT TISSUE SARCOMAS. Veterinary Radiology & Ultrasound, 51(3), 349-355. https://doi.org/https://doi.org/10.1111/j.1740-8261.2009.01661.x [85] Kliczkowska, K., Jankowska, U., Jagielski, D., Czopowicz, M., & Sapierzyński, R. (2015). Epidemiological and morphological analysis of feline injection site sarcomas. Pol J Vet Sci, 18(2), 313-322. https://doi.org/10.1515/pjvs-2015-0041 [86] Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H.-J., Nadler, P. I., Wood, D. L., Fujimori, M., Inada, T., Kouji, H., & McWilliams, R. R. (2016). Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. Journal of Clinical Oncology, 34(15_suppl), e15721-e15721. https://doi.org/10.1200/JCO.2016.34.15_suppl.e15721 [87] Kobayashi, T., Hauck, M. L., Dodge, R., Page, R. L., Price, G. S., Williams, L. E., Hardie, E. M., Mathews, K. G., & Thrall, D. E. (2002). Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound, 43(5), 473-479. https://doi.org/10.1111/j.1740-8261.2002.tb01036.x [88] Koelman, E. M. R., Yeste-Vázquez, A., & Grossmann, T. N. (2022). Targeting the interaction of β-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling. Bioorganic & Medicinal Chemistry, 70, 116920. https://doi.org/https://doi.org/10.1016/j.bmc.2022.116920 [89] Kuhnen, C., Herter, P., Müller, O., Muehlberger, T., Krause, L., Homann, H., Steinau, H. U., & Müller, K. M. (2000). Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod Pathol, 13(9), 1005-1013. https://doi.org/10.1038/modpathol.3880181 [90] Kuntz, C. A., Dernell, W. S., Powers, B. E., Devitt, C., Straw, R. C., & Withrow, S. J. (1997). Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc, 211(9), 1147-1151. [91] Le Loarer, F., Watson, S., Pierron, G., de Montpreville, V. T., Ballet, S., Firmin, N., Auguste, A., Pissaloux, D., Boyault, S., Paindavoine, S., Dechelotte, P. J., Besse, B., Vignaud, J. M., Brevet, M., Fadel, E., Richer, W., Treilleux, I., Masliah-Planchon, J., Devouassoux-Shisheboran, M.,…Tirode, F. (2015). SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet, 47(10), 1200-1205. https://doi.org/10.1038/ng.3399 [92] Lenz, H. J., & Kahn, M. (2014). Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci, 105(9), 1087-1092. https://doi.org/10.1111/cas.12471 [93] Li, C., Cao, J., Zhang, N., Tu, M., Xu, F., Wei, S., Chen, X., & Xu, Y. (2018). Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor. Sci Rep, 8(1), 14244. https://doi.org/10.1038/s41598-018-32652-3 [94] Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., & He, X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 108(6), 837-847. https://doi.org/10.1016/s0092-8674(02)00685-2 [95] Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022). Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy, 7(1), 3. https://doi.org/10.1038/s41392-021-00762-6 [96] Liu, Y. (2020). A code within the genetic code: codon usage regulates co-translational protein folding. Cell Communication and Signaling, 18(1), 145. https://doi.org/10.1186/s12964-020-00642-6 [97] Liu, Y., Patel, L., Mills, G. B., Lu, K. H., Sood, A. K., Ding, L., Kucherlapati, R., Mardis, E. R., Levine, D. A., Shmulevich, I., Broaddus, R. R., & Zhang, W. (2014). Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst, 106(9). https://doi.org/10.1093/jnci/dju245 [98] Lu, C.-H., Yu, S.-H., Wu, C.-H., Yeh, J. L.-S., Chang, H.-W., Jeng, C.-R., & Chang, Y.-C. (2023). Effects of selective cyclooxygenase-2 inhibitor robenacoxib on primary cells derived from feline injection-site sarcoma. Journal of Cellular and Molecular Medicine, 27(15), 2183-2193. https://doi.org/https://doi.org/10.1111/jcmm.17717 [99] Ma, H., Nguyen, C., Lee, K. S., & Kahn, M. (2005). Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene, 24(22), 3619-3631. https://doi.org/10.1038/sj.onc.1208433 [100] Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V., Ghosh, K., Virshup, I. H., Manoharan, V., Ong, E. H., Sangthongpitag, K., Hill, J., Petretto, E., Keller, T. H., Lee, M. A., Matter, A., & Virshup, D. M. (2016). Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene, 35(17), 2197-2207. https://doi.org/10.1038/onc.2015.280 [101] Magi, G. E., Mari, S., Renzoni, G., & Rossi, G. (2010). Immunohistochemical Expression of COX-2 in Feline Injection Site Sarcoma. Journal of Comparative Pathology, 143(4), 340. https://doi.org/https://doi.org/10.1016/j.jcpa.2010.09.110 [102] Maier, T., Stoiber, S., Gurnhofer, E., Haas, M., Kenner, L., Heiduschka, G., Kadletz-Wanke, L., & Brkic, F. F. (2023). Inhibition of beta-catenin shows therapeutic potential in head and neck squamous cell carcinoma in vitro. Eur Arch Otorhinolaryngol, 280(1), 399-408. https://doi.org/10.1007/s00405-022-07598-y [103] Maier, T., Stoiber, S., Gurnhofer, E., Haas, M., Kenner, L., Heiduschka, G., Kadletz-Wanke, L., & Brkic, F. F. (2023). Inhibition of beta-catenin shows therapeutic potential in head and neck squamous cell carcinoma in vitro. European Archives of Oto-Rhino-Laryngology, 280(1), 399-408. https://doi.org/10.1007/s00405-022-07598-y [104] Maier, T. J., Janssen, A., Schmidt, R., Geisslinger, G., & Grösch, S. (2005). Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Faseb j, 19(10), 1353-1355. https://doi.org/10.1096/fj.04-3274fje [105] Martano, M., Morello, E., Ughetto, M., Iussich, S., Petterino, C., Cascio, P., & Buracco, P. (2005). Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases. Vet J, 170(1), 84-90. https://doi.org/10.1016/j.tvjl.2004.04.004 [106] Martinez-Font, E., Felipe-Abrio, I., Calabuig-Fariñas, S., Ramos, R., Terrasa, J., Vögler, O., Alemany, R., Martín-Broto, J., & Obrador-Hevia, A. (2017). Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells. Mol Cancer Ther, 16(6), 1166-1176. https://doi.org/10.1158/1535-7163.Mct-16-0585 [107] Martinez-Font, E., Pérez-Capó, M., Vögler, O., Martín-Broto, J., Alemany, R., & Obrador-Hevia, A. (2021). WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities? Cancers (Basel), 13(21). https://doi.org/10.3390/cancers13215521 [108] Mayer, M. N., Treuil, P. L., & LaRue, S. M. (2009). Radiotherapy and surgery for feline soft tissue sarcoma. Vet Radiol Ultrasound, 50(6), 669-672. https://doi.org/10.1111/j.1740-8261.2009.01601.x [109] Mazzu, Y. Z., Hu, Y., Shen, Y., Tuschl, T., & Singer, S. (2019). miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling. Sci Rep, 9(1), 3197. https://doi.org/10.1038/s41598-019-39560-0 [110] McCleary, N. J., Sato, K., Nishihara, R., Inamura, K., Morikawa, T., Zhang, X., Wu, K., Yamauchi, M., Kim, S. A., Sukawa, Y., Mima, K., Qian, Z. R., Fuchs, C. S., Ogino, S., & Meyerhardt, J. A. (2016). Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clin Cancer Res, 22(6), 1489-1498. https://doi.org/10.1158/1078-0432.Ccr-15-0946 [111] McEntee, M. C., & Page, R. L. (2001). Feline Vaccine-Associated Sarcomas. Journal of Veterinary Internal Medicine, 15(3), 176-182. https://doi.org/https://doi.org/10.1111/j.1939-1676.2001.tb02308.x [112] McGough, I. J., & Vincent, J. P. (2016). Exosomes in developmental signalling. Development, 143(14), 2482-2493. https://doi.org/10.1242/dev.126516 [113] Mlodzik, M. (2002). Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? Trends Genet, 18(11), 564-571. https://doi.org/10.1016/s0168-9525(02)02770-1 [114] Moore, K. N., Gunderson, C. C., Sabbatini, P., McMeekin, D. S., Mantia-Smaldone, G., Burger, R. A., Morgan, M. A., Kapoun, A. M., Brachmann, R. K., Stagg, R., Farooki, A., & O'Cearbhaill, R. E. (2019). A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol, 154(2), 294-301. https://doi.org/10.1016/j.ygyno.2019.04.001 [115] Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 275(5307), 1787-1790. https://doi.org/10.1126/science.275.5307.1787 [116] Multhoff, G., Molls, M., & Radons, J. (2011). Chronic inflammation in cancer development. Front Immunol, 2, 98. https://doi.org/10.3389/fimmu.2011.00098 [117] Munday, J. S., Stedman, N. L., & Richey, L. J. (2003). Histology and immunohistochemistry of seven ferret vaccination-site fibrosarcomas. Vet Pathol, 40(3), 288-293. https://doi.org/10.1354/vp.40-3-288 [118] Murphy, B. G., Wolf, T., Vogel, H., Castillo, D., & Woolard, K. (2020). An RNA-Directed Gene Editing Strategy for Attenuating the Infectious Potential of Feline Immunodeficiency Virus-Infected Cells: A Proof of Concept. Viruses, 12(5). https://doi.org/10.3390/v12050511 [119] Nagayama, S., Fukukawa, C., Katagiri, T., Okamoto, T., Aoyama, T., Oyaizu, N., Imamura, M., Toguchida, J., & Nakamura, Y. (2005). Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene, 24(41), 6201-6212. https://doi.org/10.1038/sj.onc.1208780 [120] Najdi, R., Proffitt, K., Sprowl, S., Kaur, S., Yu, J., Covey, T. M., Virshup, D. M., & Waterman, M. L. (2012). A uniform human Wnt expression library reveals a shared secretory pathway and unique signaling activities. Differentiation, 84(2), 203-213. https://doi.org/10.1016/j.diff.2012.06.004 [121] Nambiar, P. R., Jackson, M. L., Ellis, J. A., Chelack, B. J., Kidney, B. A., & Haines, D. M. (2001). Immunohistochemical Detection of Tumor Suppressor Gene p53 Protein in Feline Injection Site-associated Sarcomas. Veterinary Pathology, 38(2), 236-238. https://doi.org/10.1354/vp.38-2-236 [122] Niehrs, C. (2012). The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol, 13(12), 767-779. https://doi.org/10.1038/nrm3470 [123] Nielsen, T. O., Poulin, N. M., & Ladanyi, M. (2015). Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov, 5(2), 124-134. https://doi.org/10.1158/2159-8290.Cd-14-1246 [124] Nieto, A., Sánchez, M. A., Martínez, E., & Rollán, E. (2003). Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-alpha in feline vaccine-associated sarcomas. Vet Pathol, 40(6), 651-658. https://doi.org/10.1354/vp.40-6-651 [125] Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., & Hedge, P. (1991). Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 253(5020), 665-669. https://doi.org/10.1126/science.1651563 [126] Nusse, R., & Clevers, H. (2017). Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 169(6), 985-999. https://doi.org/10.1016/j.cell.2017.05.016 [127] Pak, S., Park, S., Kim, Y., Park, J. H., Park, C. H., Lee, K. J., Kim, C. S., & Ahn, H. (2019). The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. J Exp Clin Cancer Res, 38(1), 342. https://doi.org/10.1186/s13046-019-1342-5 [128] Phelps, H. A., Kuntz, C. A., Milner, R. J., Powers, B. E., & Bacon, N. J. (2011). Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002). J Am Vet Med Assoc, 239(1), 97-106. https://doi.org/10.2460/javma.239.1.97 [129] Pinto, D., & Clevers, H. (2005). Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res, 306(2), 357-363. https://doi.org/10.1016/j.yexcr.2005.02.022 [130] Poirier, V. J., Thamm, D. H., Kurzman, I. D., Jeglum, K. A., Chun, R., Obradovich, J. E., O'Brien, M., Fred, R. M., 3rd, Phillips, B. S., & Vail, D. M. (2002). Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med, 16(6), 726-731. [131] Porcellato, I., Menchetti, L., Brachelente, C., Sforna, M., Reginato, A., Lepri, E., & Mechelli, L. (2016). Feline Injection-Site Sarcoma: Matrix Remodeling and Prognosis. Veterinary Pathology, 54(2), 204-211. https://doi.org/10.1177/0300985816677148 [132] Porcellato, I., Menchetti, L., Brachelente, C., Sforna, M., Reginato, A., Lepri, E., & Mechelli, L. (2017). Feline Injection-Site Sarcoma:Matrix Remodeling and Prognosis. Veterinary Pathology, 54(2), 204-211. https://doi.org/10.1177/0300985816677148 [133] Putnová, B., Putnová, I., Škorič, M., & Buchtová, M. (2021). The Expression of Selected Wnt Pathway Members (FZD6, AXIN2 and β-Catenin) in Canine Oral Squamous Cell Carcinoma and Acanthomatous Ameloblastoma. Animals, 11(6). [134] Rassnick, K. M., Rodriguez, C. O., Khanna, C., Rosenberg, M. P., Kristal, O., Chaffin, K., & Page, R. L. (2006). Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. Am J Vet Res, 67(3), 517-523. https://doi.org/10.2460/ajvr.67.3.517 [135] Rebel, V. I., Kung, A. L., Tanner, E. A., Yang, H., Bronson, R. T., & Livingston, D. M. (2002). Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A, 99(23), 14789-14794. https://doi.org/10.1073/pnas.232568499 [136] Rebouissou, S., Franconi, A., Calderaro, J., Letouzé, E., Imbeaud, S., Pilati, C., Nault, J. C., Couchy, G., Laurent, A., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2016). Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology, 64(6), 2047-2061. https://doi.org/10.1002/hep.28638 [137] Rios-Esteves, J., Haugen, B., & Resh, M. D. (2014). Identification of key residues and regions important for porcupine-mediated Wnt acylation. J Biol Chem, 289(24), 17009-17019. https://doi.org/10.1074/jbc.M114.561209 [138] Rios-Esteves, J., & Resh, M. D. (2013). Stearoyl CoA desaturase is required to produce active, lipid-modified Wnt proteins. Cell Rep, 4(6), 1072-1081. https://doi.org/10.1016/j.celrep.2013.08.027 [139] Roth, J. F., Shikama, N., Henzen, C., Desbaillets, I., Lutz, W., Marino, S., Wittwer, J., Schorle, H., Gassmann, M., & Eckner, R. (2003). Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. Embo j, 22(19), 5186-5196. https://doi.org/10.1093/emboj/cdg473 [140] Saba, C. F., Vail, D. M., & Thamm, D. H. (2012). Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. Vet Comp Oncol, 10(4), 283-291. https://doi.org/10.1111/j.1476-5829.2011.00295.x [141] Säfholm, A., Leandersson, K., Dejmek, J., Nielsen, C. K., Villoutreix, B. O., & Andersson, T. (2006). A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem, 281(5), 2740-2749. https://doi.org/10.1074/jbc.M508386200 [142] Saha, S., Aranda, E., Hayakawa, Y., Bhanja, P., Atay, S., Brodin, N. P., Li, J., Asfaha, S., Liu, L., Tailor, Y., Zhang, J., Godwin, A. K., Tome, W. A., Wang, T. C., Guha, C., & Pollard, J. W. (2016). Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury. Nat Commun, 7, 13096. https://doi.org/10.1038/ncomms13096 [143] Sammarco, A., Gomiero, C., Sacchetto, R., Beffagna, G., Michieletto, S., Orvieto, E., Cavicchioli, L., Gelain, M. E., Ferro, S., Patruno, M., & Zappulli, V. (2020). Wnt/β-Catenin and Hippo Pathway Deregulation in Mammary Tumors of Humans, Dogs, and Cats. Veterinary Pathology, 57(6), 774-790. https://doi.org/10.1177/0300985820948823 [144] Sampietro, J., Dahlberg, C. L., Cho, U. S., Hinds, T. R., Kimelman, D., & Xu, W. (2006). Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Mol Cell, 24(2), 293-300. https://doi.org/10.1016/j.molcel.2006.09.001 [145] Santelices Iglesias, O. A., Wright, C., Duchene, A. G., Risso, M. A., Risso, P., Zanuzzi, C. N., Nishida, F., Lavid, A., Confente, F., Díaz, M., Portiansky, E. L., Gimeno, E. J., & Barbeito, C. G. (2018). Association between Degree of Anaplasia and Degree of Inflammation with the Expression of COX-2 in Feline Injection Site Sarcomas. J Comp Pathol, 165, 45-51. https://doi.org/10.1016/j.jcpa.2018.09.002 [146] Scherk, M. A., Ford, R. B., Gaskell, R. M., Hartmann, K., Hurley, K. F., Lappin, M. R., Levy, J. K., Little, S. E., Nordone, S. K., & Sparkes, A. H. (2013). 2013 AAFP Feline Vaccination Advisory Panel Report. J Feline Med Surg, 15(9), 785-808. https://doi.org/10.1177/1098612x13500429 [147] Shaw, S. C., Kent, M. S., Gordon, I. K., Collins, C. J., Greasby, T. A., Beckett, L. A., Hammond, G. M., & Skorupski, K. A. (2009). Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990-2006). J Am Vet Med Assoc, 234(3), 376-380. https://doi.org/10.2460/javma.234.3.376 [148] Shih, C.-H., Chang, Y.-C., Lai, Y.-C., & Chiou, H.-Y. (2022). Investigating the role of signal transducer and activator of transcription 3 in feline injection site sarcoma. BMC Veterinary Research, 18(1), 276. https://doi.org/10.1186/s12917-022-03352-y [149] Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C. Y., Marchetti, A., Borsu, L., Barr, F. G., & Ladanyi, M. (2012). Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res, 18(3), 748-757. https://doi.org/10.1158/1078-0432.Ccr-11-2056 [150] Singh, V., Walter, V., Elcheva, I., Imamura Kawasawa, Y., & Spiegelman, V. S. (2023). Global role of IGF2BP1 in controlling the expression of Wnt/β-catenin-regulated genes in colorectal cancer cells. Front Cell Dev Biol, 11, 1236356. https://doi.org/10.3389/fcell.2023.1236356 [151] Steinhusen, U., Badock, V., Bauer, A., Behrens, J., Wittman-Liebold, B., Dörken, B., & Bommert, K. (2000). Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem, 275(21), 16345-16353. https://doi.org/10.1074/jbc.M001458200 [152] Su, M.-C., Huang, W.-C., & Lien, H.-C. (2008). Beta-catenin expression and mutation in adult and pediatric Wilms' tumors. APMIS, 116(9), 771-778. https://doi.org/https://doi.org/10.1111/j.1600-0463.2008.00914.x [153] Subramaniam, M. M., Calabuig-Fariñas, S., Pellin, A., & Llombart-Bosch, A. (2010). Mutational analysis of E-cadherin, β-catenin and APC genes in synovial sarcomas. Histopathology, 57(3), 482-486. https://doi.org/10.1111/j.1365-2559.2010.03626.x [154] Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., Takao, T., & Takada, S. (2006). Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell, 11(6), 791-801. https://doi.org/10.1016/j.devcel.2006.10.003 [155] Tam, B. Y., Chiu, K., Chung, H., Bossard, C., Nguyen, J. D., Creger, E., Eastman, B. W., Mak, C. C., Ibanez, M., Ghias, A., Cahiwat, J., Do, L., Cho, S., Nguyen, J., Deshmukh, V., Stewart, J., Chen, C. W., Barroga, C., Dellamary, L.,…Yazici, Y. (2020). The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett, 473, 186-197. https://doi.org/10.1016/j.canlet.2019.09.009 [156] Tang, S., Zhao, Y., He, X., Zhu, J., Chen, S., Wen, J., & Deng, Y. (2020). Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition. RNA Biol, 17(6), 881-891. https://doi.org/10.1080/15476286.2020.1734372 [157] Taniguchi, K., Roberts, L. R., Aderca, I. N., Dong, X., Qian, C., Murphy, L. M., Nagorney, D. M., Burgart, L. J., Roche, P. C., Smith, D. I., Ross, J. A., & Liu, W. (2002). Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 21(31), 4863-4871. https://doi.org/10.1038/sj.onc.1205591 [158] Tejpar, S., Nollet, F., Li, C., Wunder, J. S., Michils, G., dal Cin, P., Van Cutsem, E., Bapat, B., van Roy, F., Cassiman, J. J., & Alman, B. A. (1999). Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene, 18(47), 6615-6620. https://doi.org/10.1038/sj.onc.1203041 [159] Teneggi, V., Ng, M., Tan, D. S., Subbiah, V., Weekes, C., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Gan, S., Blanchard, S., Nellore, R., Lee, M. A., Hill, J., Virshup, D., Madan, B., & Matter, A. (2016). 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. Annals of Oncology, 27, ix47. https://doi.org/10.1016/S0923-7534(21)00310-0 [160] Teulière, J., Faraldo, M. M., Deugnier, M. A., Shtutman, M., Ben-Ze'ev, A., Thiery, J. P., & Glukhova, M. A. (2005). Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development, 132(2), 267-277. https://doi.org/10.1242/dev.01583 [161] Trautmann, M., Sievers, E., Aretz, S., Kindler, D., Michels, S., Friedrichs, N., Renner, M., Kirfel, J., Steiner, S., Huss, S., Koch, A., Penzel, R., Larsson, O., Kawai, A., Tanaka, S., Sonobe, H., Waha, A., Schirmacher, P., Mechtersheimer, G.,…Hartmann, W. (2014). SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene, 33(42), 5006-5016. https://doi.org/10.1038/onc.2013.443 [162] Travetti, O., di Giancamillo, M., Stefanello, D., Ferrari, R., Giudice, C., Grieco, V., & Saunders, J. H. (2013). Computed tomography characteristics of fibrosarcoma -- a histological subtype of feline injection-site sarcoma. J Feline Med Surg, 15(6), 488-493. https://doi.org/10.1177/1098612x12472174 [163] Trojani, M., Contesso, G., Coindre, J. M., Rouesse, J., Bui, N. B., de Mascarel, A., Goussot, J. F., David, M., Bonichon, F., & Lagarde, C. (1984). Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer, 33(1), 37-42. https://doi.org/10.1002/ijc.2910330108 [164] Uren, A., Wolf, V., Sun, Y. F., Azari, A., Rubin, J. S., & Toretsky, J. A. (2004). Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer, 43(3), 243-249. https://doi.org/10.1002/pbc.20124 [165] Vaccine-Associated Feline Sarcoma Task Force guidelines. Diagnosis and treatment of suspected sarcomas. (1999). J Am Vet Med Assoc, 214(12), 1745. [166] Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022). Senescence-Associated β-Galactosidase Detection in Pathology. Diagnostics (Basel), 12(10). https://doi.org/10.3390/diagnostics12102309 [167] Vascellari, M., Melchiotti, E., Bozza, M. A., & Mutinelli, F. (2003). Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas. J Vet Med A Physiol Pathol Clin Med, 50(6), 286-291. https://doi.org/10.1046/j.1439-0442.2003.00544.x [168] Vijayakumar, S., Liu, G., Rus, I. A., Yao, S., Chen, Y., Akiri, G., Grumolato, L., & Aaronson, S. A. (2011). High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell, 19(5), 601-612. https://doi.org/10.1016/j.ccr.2011.03.010 [169] Wei, Q., Ramsey, S. A., Larson, M. K., Berlow, N. E., Ochola, D., Shiprack, C., Kashyap, A., Séguin, B., Keller, C., & Löhr, C. V. (2019). Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach. BMC Cancer, 19(1), 311. https://doi.org/10.1186/s12885-019-5501-z [170] Wilcock, B., Wilcock, A., & Bottoms, K. (2012). Feline postvaccinal sarcoma: 20 years later. Can Vet J, 53(4), 430-434. [171] Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., 3rd, & Nusse, R. (2003). Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature, 423(6938), 448-452. https://doi.org/10.1038/nature01611 [172] Williams, C. S., Mann, M., & DuBois, R. N. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18(55), 7908-7916. https://doi.org/10.1038/sj.onc.1203286 [173] Xing, Y., Clements, W. K., Le Trong, I., Hinds, T. R., Stenkamp, R., Kimelman, D., & Xu, W. (2004). Crystal structure of a beta-catenin/APC complex reveals a critical role for APC phosphorylation in APC function. Mol Cell, 15(4), 523-533. https://doi.org/10.1016/j.molcel.2004.08.001 [174] Xing, Y., Takemaru, K., Liu, J., Berndt, J. D., Zheng, J. J., Moon, R. T., & Xu, W. (2008). Crystal structure of a full-length beta-catenin. Structure, 16(3), 478-487. https://doi.org/10.1016/j.str.2007.12.021 [175] Xu, T., Zhang, Y., Zhang, J., Qi, C., Liu, D., Wang, Z., Li, Y., Ji, C., Li, J., Lin, X., Hou, T., Liu, H., Zhang, L., Han-Zhang, H., Shen, L., & Wang, X. (2020). Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. Front Oncol, 10, 568911. https://doi.org/10.3389/fonc.2020.568911 [176] Xu, W., & Kimelman, D. (2007). Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci, 120(Pt 19), 3337-3344. https://doi.org/10.1242/jcs.013771 [177] Yao, T. P., Oh, S. P., Fuchs, M., Zhou, N. D., Ch'ng, L. E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998). Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell, 93(3), 361-372. https://doi.org/10.1016/s0092-8674(00)81165-4 [178] Yardy, G. W., Bicknell, D. C., Wilding, J. L., Bartlett, S., Liu, Y., Winney, B., Turner, G. D., Brewster, S. F., & Bodmer, W. F. (2009). Mutations in the AXIN1 gene in advanced prostate cancer. Eur Urol, 56(3), 486-494. https://doi.org/10.1016/j.eururo.2008.05.029 [179] Ye, C., Qi, L., Li, X., Wang, J., Yu, J., Zhou, B., Guo, C., Chen, J., & Zheng, S. (2020). Targeting the NAD(+) salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level. Cell Commun Signal, 18(1), 16. https://doi.org/10.1186/s12964-020-0513-5 [180] Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D., & Moon, R. T. (1996). The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev, 10(12), 1443-1454. https://doi.org/10.1101/gad.10.12.1443 [181] Yu, J., Chia, J., Canning, C. A., Jones, C. M., Bard, F. A., & Virshup, D. M. (2014). WLS retrograde transport to the endoplasmic reticulum during Wnt secretion. Dev Cell, 29(3), 277-291. https://doi.org/10.1016/j.devcel.2014.03.016 [182] Yu, P., Wang, Y., Yu, Y., Wang, A., Huang, L., Zhang, Y., Liu, W., Wu, H., Yao, M., Du, Y. A., & Cheng, X. (2021). Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma. Oncologist, 26(5), e756-e768. https://doi.org/10.1002/onco.13695 [183] Zabielska, K., Lechowski, R., Król, M., Pawłowski, K. M., Motyl, T., Dolka, I., & Zbikowski, A. (2012). Derivation of feline vaccine-associated fibrosarcoma cell line and its growth on chick embryo chorioallantoic membrane - a new in vivo model for veterinary oncological studies. Vet Res Commun, 36(4), 227-233. https://doi.org/10.1007/s11259-012-9535-9 [184] Zabielska-Koczywąs, K., Wojtalewicz, A., & Lechowski, R. (2017). Current knowledge on feline injection-site sarcoma treatment. Acta Veterinaria Scandinavica, 59(1), 47. https://doi.org/10.1186/s13028-017-0315-y [185] Zhan, T., Rindtorff, N., & Boutros, M. (2017). Wnt signaling in cancer. Oncogene, 36(11), 1461-1473. https://doi.org/10.1038/onc.2016.304 [186] Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021). Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 6(1), 263. https://doi.org/10.1038/s41392-021-00658-5 [187] Zhong, Z., Sepramaniam, S., Chew, X. H., Wood, K., Lee, M. A., Madan, B., & Virshup, D. M. (2019). PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene, 38(40), 6662-6677. https://doi.org/10.1038/s41388-019-0908-1 | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/101235 | - |
| dc.description.abstract | 貓注射部位肉瘤（Feline injection-site sarcoma, FISS） 是一種高度惡性且具有 強烈組織侵犯性的軟組織腫瘤， 即使在接受大範圍手術切除後， 復發率仍相當高。 儘管已有研究指出， 大範圍手術切除合併放射線治療可延長無病生存期， 但目前 在獸醫領域的放射線治療資源有限，故 FISS 的治療在臨床上仍相當有挑戰性。 此外，雖然慢性發炎已被廣泛被認為是 FISS 的誘發因子，但其確切致病機轉尚 未完全釐清， 目前已有多項研究指出，多種發炎相關的訊息傳遞路徑， 例如 COX- 2、 NF-κB 及 STAT3， 可能與 FISS 的發生和進展有密切相關。 另一方面， WNT/β- catenin 訊息傳遞路徑在維持細胞恆定中扮演重要角色，並日益被認為與人類及 獸醫腫瘤之形成有關，其中 β-catenin 基因（CTNNB1）的突變已知可促使多種 人類癌症的腫瘤轉化。為探討此訊息傳遞路徑是否參與 FISS 的腫瘤生成，我們 檢測 β-catenin 在 mRNA 與蛋白質層級的表現 ，並進行 CTNNB1 全長定序。 結果 顯示 ，在福馬林固定石蠟包埋組織與 FISS 初代細胞中皆可觀察到 β-catenin 在細 胞質內的累積，而且所有 FISS 細胞株的 β-catenin 蛋白質表現量皆顯著高於正常 貓皮膚組織，然而即時定量聚合酶連鎖反應（RT-qPCR） 的結果顯示，FISS 細胞 中 β-catenin mRNA 表現量低於正常組織，推測可能與轉譯後調控有關。進一步 分析 CTNNB1 序列可發現數個點突變，部分突變會導致胺基酸置換，包含一處 位於 β-TrCP 結合區之人類癌症突變熱點， 已知可增強 β-catenin 的穩定性與促癌 訊號活性。為了進一步評估 β-catenin 抑制劑 MSAB 對於 FISS 的治療效果 ，我們 以 FISS 初代細胞進行多種功能測試， 結果發現 MSAB 能顯著抑制細胞增殖、 聚 落形成與細胞移行。 綜上所述 ，本研究結果支持 FISS 發展過程中 WNT/β-catenin 訊息傳遞路徑可能會發生異常， 凸顯此訊息傳遞路徑具備作為藥物研發靶點的潛 力。此外，我們亦嘗試建立雞胚尿囊絨毛膜 （chorioallantoic membrane, CAM） 模 型， 作為替代性動物模型來評估藥物療效 ，此模型相較於傳統鼠類模型在實驗動 物減量與實驗操作方面具有實用優勢， 可應用於新型 FISS 治療藥物的快速篩選。 | zh_TW |
| dc.description.abstract | Feline injection-site sarcoma (FISS) is a highly malignant and locally invasive soft tissue sarcoma characterized by a high recurrence rate even after radical surgical resection. Although combination of wide-margin excision and radiation therapy has been reported to prolong disease-free intervals, the limited availability of radiotherapy in veterinary medicine continues to impede optimal clinical management. Moreover, the precise pathogenesis of FISS remains unclear, although chronic inflammation is widely considered as a key factor. Multiple studies have indicated that various inflammatory signaling pathways, such as COX-2, NF-κB, and STAT3, may contribute to the initiation and progression of FISS. Meanwhile, the WNT/β-catenin signaling pathway, which plays a fundamental role in maintaining cellular homeostasis, has also been increasingly associated with tumorigenesis in both human and veterinary tumors, and mutations in the β-catenin gene (CTNNB1) are known to promote neoplastic transformation in several human cancers. To investigate the potential involvement of this pathway in FISS, we evaluated β-catenin expression at both the mRNA and protein levels and analyzed the full-length sequence of CTNNB1 gene. Our findings demonstrated increased amounts of β-catenin accumulated in the cytoplasm of formalin-fixed paraffin-embedded FISS tissues and primary FISS cells. Additionally, western blot analysis revealed that β-catenin protein levels of all FISS cell lines were markedly elevated when compared to those of normal feline skin tissue. However, the mRNA expression levels of β-catenin in FISS cells were lower than in normal tissue by using quantitative real-time PCR, suggestive of possible post-transcriptional regulation. Several point mutations, some of which lead to amino acid substitution, in CTNNB1 were identified. One mutation located in the β-TrCP binding domain was the reported hotspot in human cancers and known for enhancing β-catenin stability and oncogenic signaling. To investigate the potential therapeutic potential of MSAB, a β-catenin inhibitor, on FISS, several functional assays were conducted. Our results revealed that MSAB could significantly inhibit cell proliferation, clonogenesis, and cell migration. , These findings support that WNT/β-catenin signaling is dysregulated during FISS development and might be a potential target for drug intervention. On the other hand, we sought to establish a chick embryo chorioallantoic membrane (CAM) model as an alternative in vivo platform to evaluate drug efficacy. This model offers several practical and ethical advantages over traditional rodent models, and may facilitate the screening of novel therapeutic candidates against FISS. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-12-31T16:25:06Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-12-31T16:25:06Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | CONTENTS
致謝 i 中文摘要 ii Abstract iv CONTENTS vi LIST OF FIGURES ix LIST OF TABLES x Chapter 1 Introduction 1 1.1 Feline injection-site sarcoma (FISS) 1 1.1.1 Overview 1 1.1.2 Epidemiology 1 1.1.3 Gross and histopathological findings 2 1.1.4 Biological behavior 4 1.1.5 Treatments 4 1.1.6 Prognosis 6 1.1.7 Prevention 6 1.2 Tumorigenesis of FISS 7 1.2.1 Pathogenesis of FISS 7 1.3 The involvement of WNT/β-catenin signaling pathway in tumor development 9 1.3.1 Overview of the WNT/β-catenin signaling pathway 9 1.3.2 The involvement of WNT/β-catenin signaling pathway in the development of human tumors 12 1.3.3 Aberrant activation of the WNT/β-catenin signaling pathway in cancer development in animals 16 1.4 Therapeutic approaches for tumors 17 1.4.1 Therapeutic approaches targeting the upstream of β-catenin activation 18 1.4.2 Intervention strategies targeting downstream β-catenin signaling 21 1.5 MSAB as a potential therapeutic agent targeting the WNT/β-catenin pathway 22 1.6 Aims of the study 23 Chapter 2 Materials and methods 24 2.1. Isolation and primary culture of feline injection site sarcoma (FISS) cell lines 24 2.2. The β-catenin gene sequencing in different FISS primary cell lines 25 2.2.1. RNA extraction and cDNA synthesis 25 2.2.2. Polymerase chain reaction (PCR) and gene sequencing and analysis 25 2.3. The β-catenin expression levels in different FISS primary cell lines 26 2.3.1. RNA extraction, cDNA synthesis and quantitative real-time PCR (qPCR) 26 2.3.2. Western blotting 27 2.3.3. Immunocytochemistry staining (ICC) 28 2.4. The β-catenin expression levels in formalin-fixed paraffin-embedded (FFPE) tissue of clinical FISS samples 29 2.4.1. Immunohistochemistry (IHC) staining 29 2.4.2. IHC scoring system 30 2.5. Therapeutic evaluation of β-catenin inhibitor in FISSs 30 2.5.1. Reagents 30 2.5.2. Cell viability 31 2.5.3. Wound healing assay 32 2.5.4. Clonogenic assay 33 2.5.5. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 34 2.6. FISS cell line growth on chick embryo chorioallantoic membrane 35 2.7. Impact of MSAB on WNT/β-catenin signaling in FISS cells 36 2.8. Statistical analysis 36 Chapter 3 Results 37 3.1 The β-catenin expression levels in FISS cells assessed by western blot analysis, immunocytochemistry (ICC) staining, and quantitative real-time PCR (qPCR) 37 3.2 The β-catenin expression levels in FFPE tissues of clinical specimens detected by immunohistochemical (IHC) staining 37 3.3 Analysis of the nucleotide and amino acid sequences of β-catenin genes in different FISS cell lines 38 3.4 The half-maximal inhibitory concentrations (IC50) of MSAB in different FISS cell lines and feline mesenchymal cells 39 3.5 The effect of MSAB on triggering apoptosis and necrosis in different FISS cell lines 39 3.6 The inhibitory effects of MSAB on clonogenic ability in different FISS cell lines 40 3.7 The effect of MSAB on the migratory ability in different FISS cell lines 41 3.8 Establishment of the chick embryo chorioallantoic membrane (CAM) model of FISS 41 3.9 The impact of MSAB on the WNT/β-catenin signaling pathway 42 Chapter 4 Discussion 43 Reference 92 LIST OF FIGURES Figure 1. The β-catenin expression in FISS cell lines and feline mesenchymal cells by using immunocytochemical (ICC) staining 68 Figure 2. The protein expression of β-catenin in FISS cell lines, normal feline skin tissue, and feline mesenchymal cells detected by western blot 69 Figure 3. The semi-quantification of β-catenin mRNA level in FISS cell lines and normal feline skin tissue by using reverse transcription real-time PCR (RT-qPCR) 70 Figure 4. The immunohistochemical (IHC) results of β-catenin expression in formalin-fixed and paraffin-embedded (FFPE) tissues from clinical feline injection site sarcoma cases 71 Figure 5. The nucleotide and amino acid sequences of the β-catenin gene in different FISS cell lines and feline mesenchymal cells 76 Figure 6. The half maximal inhibitory concentration (IC50) of MSAB in FISS cell lines and normal feline mesenchymal cells at 24 and 72 hours 79 Figure 7. The apoptotic rates and cell viabilities of FISS cell lines after treated with different concentrations of MSAB 81 Figure 8. The clonogenic abilities of FISS cell lines following MSAB treatments 83 Figure 9. The alteration of cell migration of FISS cells following 24-hour MSAB treatment 86 Figure 10. The result of chick embryo chorioallantoic membrane (CAM) model for FISS cell lines 88 Figure 11. The impact of MSAB therapy on WNT/β-catenin pathway activity in FISS cells 91 LIST OF TABLES Table 1. Primer pairs used for quantitative real-time PCR (qPCR) targeting β-catenin, β-actin and GAPDH genes 54 Table 2. Primer sets designed for full-length β-catenin sequencing 55 Table 3. Signalment of 26 clinical cases for immunohistochemistry staining in the present study 56 Table 4. The immunohistochemical results of β-catenin expression in 26 feline injection-site sarcoma cases 58 Table 5. Nucleotide mutations detected in β-catenin gene of different FISS cell lines 60 Table 6. The half-maximal inhibitory concentrations (IC50) of MSAB in FISS cell lines and feline mesenchymal cells (FM) following 24- and 72-hour treatments 62 Table 7. The apoptotic rate of FISS cells following 24-hour incubation with different concentrations of MSAB 63 Table 8. The cell viability of FISS cell lines following 24-hour treatment of different concentrations of MSAB 64 Table 9. The clonogenic abilities of FISS cell lines following 72-hour treatment with different concentrations of MSAB 65 Table 10. The migratory abilities of FISS cell lines after 24-hour treatment with different concentrations of MSAB 66 Table 11. The results of chick embryo chorioallantoic membrane model using different FISS cell lines 67 | - |
| dc.language.iso | en | - |
| dc.subject | 貓注射部位肉瘤 | - |
| dc.subject | CTNNB1 | - |
| dc.subject | WNT/β-catenin 訊息傳遞路徑 | - |
| dc.subject | MSAB | - |
| dc.subject | feline injection-site sarcoma | - |
| dc.subject | CTNNB1 | - |
| dc.subject | WNT/β-catenin pathway | - |
| dc.subject | MSAB | - |
| dc.title | 探討 WNT/β-catenin 分子機制於貓注射部位肉瘤之致腫瘤機制 | zh_TW |
| dc.title | The Role of WNT/β-catenin pathway in Tumorigenesis of Feline Injection-site Sarcoma (FISS) | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 114-1 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 張惠雯;張佳瑜;邱慧英 | zh_TW |
| dc.contributor.oralexamcommittee | Hui-Wen Chang;Chia-Yu Chang;Hue-Ying Chiou | en |
| dc.subject.keyword | 貓注射部位肉瘤,CTNNB1WNT/β-catenin 訊息傳遞路徑MSAB | zh_TW |
| dc.subject.keyword | feline injection-site sarcoma,CTNNB1WNT/β-catenin pathwayMSAB | en |
| dc.relation.page | 111 | - |
| dc.identifier.doi | 10.6342/NTU202504759 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2025-12-08 | - |
| dc.contributor.author-college | 生物資源暨農學院 | - |
| dc.contributor.author-dept | 分子暨比較病理生物學研究所 | - |
| dc.date.embargo-lift | N/A | - |
| Appears in Collections: | 分子暨比較病理生物學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-114-1.pdf Restricted Access | 26.35 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.